Skip to main content
. 2021 Oct 20;8:609590. doi: 10.3389/fcvm.2021.609590

Table 3.

Baseline population demographics of included patients.

No. of studies HP CP p-value
Age 16 61.9 ± 4.4 62.0 ± 5.0 0.917
Male (%) 16 71.7 ± 9.8 69.3 ± 8.2 0.471
Hypertension 12 53.1 ± 19.7 50.4 ± 18.8 0.733
Diabetes mellitus 9 20.1 ± 12.1 15.2 ± 8.6 0.333
Stroke/TIA 8 9.0 ± 3.7 8.9 ± 2.5 0.932
CHA2DS2-VASC 9 2.0 ± 0.4 2.1 ± 0.3 0.818
LA diameter 9 41.3 ± 2.7 41.0 ± 3.3 0.837
AF duration (year) 5 3.9 ± 2.0 4.3 ± 2.2 0.793
Heart failure 5 15.1 ± 19.1 14.8 ± 18.3 0.983
LVEF (%) 10 58.6 ± 4.2 58.6 ± 4.3 0.996
CAD 4 19.3 ± 6.7 16.9 ± 6.6 0.637
BMI 8 26.7 ± 2.4 26.8 ± 2.5 0.944

HP, high-power ablation; CP, conventional-power ablation; TIA, transient ischemic attack; LA, left atrium; AF, atrial fibrillation; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; BMI, body mass index.